End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.97 CNY | +1.32% | -1.33% | +20.59% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.59% | 8.19B | B- | ||
+26.08% | 662B | C+ | ||
+21.80% | 546B | B | ||
-4.77% | 359B | C+ | ||
+16.97% | 323B | B- | ||
+5.69% | 289B | C+ | ||
+13.68% | 234B | B+ | ||
+4.21% | 198B | B- | ||
-11.25% | 194B | A+ | ||
+8.08% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000999 Stock
- Ratings China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.